Phase III, randomized, double-blind study comparing the efficacy, safety, and immunogenicity of SB3 (trastuzumab biosimilar) and reference trastuzumab in patients treated with neoadjuvant therapy for human epidermal growth factor receptor 2–positive early breast cancer
Journal of Clinical Oncology Feb 01, 2018
Pivot X, et al. - SB3, a trastuzumab (TRZ) biosimilar, was compared with reference TRZ in terms of efficacy, safety, and immunogenicity in patients with human epidermal growth factor receptor 2–positive early breast cancer in the neoadjuvant setting. On the basis of the ratio of breast pathologic complete response (bpCR) rates, SB3 and TRZ were found to be equally efficacious. In addition, both these agents demonstrated comparable safety and immunogenicity.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
